

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Maria Pia PROTTI et al.

Serial No. 09/914,239
(PCT/EP00/01458)

Box PCT
Attention: DO/EO

Filed August 23, 2001

MAGE-3 DERIVED IMMUNOGENIC PEPTIDES
PRESENTED BY MHC OF CLASS II AND
THE USE THEREOF



TRANSMITTAL LETTER

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to PCT/DO/EO/905 mailed October 9, 2001, we enclose herewith the executed declaration which was omitted at the time of filing the application.

The required 37 CFR 1.492(e) surcharge was paid at the time of filing the application.

Respectfully submitted,

YOUNG & THOMPSON

By Benoît Castel
Benoît Castel
Attorney for Applicant
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

December 4, 2001
Ref. 9369V/vmf

<input checked="" type="checkbox"/> Commissioner For Patents, Box PCT, United States Patent and Trademark Office, Washington, D.C. 20231, www.uspto.gov		
---	--	--

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
-----------------------------	-----------------------	------------------

09/914,239

Maria Pia Protti

9369 V/vmf

INTERNATIONAL APPLICATION NO.

PCT/EP00/01458


LA. FILING DATE	PRIORITY DATE
-----------------	---------------

02/23/2000

02/26/1999

000466

YOUNG & THOMPSON
745 SOUTH 23RD STREET 2ND FLOOR
ARLINGTON, VA 22202



CONFIRMATION NO. 1842

371 FORMALITIES LETTER



OC000000006845267

Date Mailed: 10/09/2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fees
- Priority Document
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Preliminary Amendments
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216

- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

DARRELL C COTTMAN

Telephone: (703) 305-3693

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/914,239	PCT/EP00/01458	9369 V/vmf